<!-- Visualization: VTE Risk by Route of Administration -->
<!-- Generated: 2025-12-23 -->
<!-- Type: comparison-bar-chart -->
<!-- Source: PMC9399360 -->

<figure class="data-viz" id="viz-6">
  <div class="viz-container" style="position: relative; width: 100%; max-width: 750px; margin: 0 auto; padding: 20px;">
    <canvas id="chart-vte-route"></canvas>
  </div>
  <div class="route-comparison">
    <div class="route-item oral">
      <div class="route-icon">&#x1F48A;</div>
      <div class="route-label">Oral HRT</div>
      <div class="route-risk">RR 1.9</div>
      <div class="route-desc">90% increased VTE risk</div>
      <div class="route-note">First-pass liver metabolism increases clotting factors</div>
    </div>
    <div class="route-item transdermal">
      <div class="route-icon">&#x1FA79;</div>
      <div class="route-label">Transdermal HRT</div>
      <div class="route-risk">RR 1.0</div>
      <div class="route-desc">No increased VTE risk</div>
      <div class="route-note">Bypasses liver, avoids clotting factor changes</div>
    </div>
  </div>
  <figcaption>
    <strong>Figure 6:</strong> Route of administration dramatically affects blood clot risk. Oral estrogen nearly doubles VTE risk through first-pass liver metabolism effects, while transdermal delivery (patches, gels, sprays) shows no increased risk. This distinction is critical for women with VTE risk factors.
    <span class="viz-source">Source: Hormonal therapies and venous thrombosis: Considerations for prevention and management. PMC9399360</span>
  </figcaption>
</figure>

<style>
.data-viz {
  margin: 2rem 0;
  padding: 1.5rem;
  background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
  border-radius: 12px;
  box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}
.route-comparison {
  display: flex;
  justify-content: center;
  gap: 2rem;
  margin: 1.5rem auto;
  max-width: 700px;
  flex-wrap: wrap;
}
.route-item {
  flex: 1;
  min-width: 250px;
  padding: 1.25rem;
  border-radius: 12px;
  text-align: center;
}
.route-item.oral {
  background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%);
  border: 2px solid #fca5a5;
}
.route-item.transdermal {
  background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%);
  border: 2px solid #86efac;
}
.route-icon {
  font-size: 2rem;
  margin-bottom: 0.5rem;
}
.route-label {
  font-weight: 700;
  font-size: 1.1rem;
  margin-bottom: 0.5rem;
}
.route-item.oral .route-label { color: #b91c1c; }
.route-item.transdermal .route-label { color: #166534; }
.route-risk {
  font-size: 1.5rem;
  font-weight: 800;
  margin-bottom: 0.25rem;
}
.route-item.oral .route-risk { color: #dc2626; }
.route-item.transdermal .route-risk { color: #22c55e; }
.route-desc {
  font-weight: 600;
  margin-bottom: 0.5rem;
  font-size: 0.95rem;
}
.route-item.oral .route-desc { color: #991b1b; }
.route-item.transdermal .route-desc { color: #166534; }
.route-note {
  font-size: 0.85rem;
  color: #64748b;
  font-style: italic;
}
.data-viz figcaption {
  text-align: center;
  margin-top: 1rem;
  font-size: 0.95rem;
  color: #475569;
  line-height: 1.6;
  max-width: 800px;
  margin-left: auto;
  margin-right: auto;
}
.viz-source {
  display: block;
  font-size: 0.8rem;
  color: #94a3b8;
  margin-top: 0.75rem;
  font-style: italic;
}
</style>

<script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
<script src="https://cdn.jsdelivr.net/npm/chartjs-plugin-annotation"></script>
<script>
(function() {
  const ctx = document.getElementById('chart-vte-route').getContext('2d');

  new Chart(ctx, {
    type: 'bar',
    data: {
      labels: ['Oral HRT', 'Transdermal HRT'],
      datasets: [{
        label: 'Relative Risk of VTE',
        data: [1.9, 1.0],
        backgroundColor: [
          'rgba(239, 68, 68, 0.8)',
          'rgba(34, 197, 94, 0.8)'
        ],
        borderColor: [
          'rgba(239, 68, 68, 1)',
          'rgba(34, 197, 94, 1)'
        ],
        borderWidth: 3,
        borderRadius: 10,
        barThickness: 100
      }]
    },
    options: {
      responsive: true,
      maintainAspectRatio: true,
      aspectRatio: 2,
      plugins: {
        title: {
          display: true,
          text: 'Venous Thromboembolism Risk: Oral vs Transdermal Delivery',
          font: { size: 18, weight: 'bold' },
          color: '#1e293b',
          padding: { bottom: 20 }
        },
        legend: {
          display: false
        },
        tooltip: {
          backgroundColor: 'rgba(15, 23, 42, 0.95)',
          titleFont: { size: 14 },
          bodyFont: { size: 13 },
          padding: 12,
          cornerRadius: 8,
          callbacks: {
            label: function(context) {
              const rr = context.raw;
              if (rr > 1) {
                return `${Math.round((rr-1)*100)}% increased risk (RR ${rr})`;
              }
              return 'No increased risk (RR 1.0)';
            }
          }
        },
        annotation: {
          annotations: {
            baselineLine: {
              type: 'line',
              yMin: 1,
              yMax: 1,
              borderColor: 'rgba(100, 116, 139, 0.8)',
              borderWidth: 2,
              borderDash: [8, 4],
              label: {
                display: true,
                content: 'Baseline (No HRT)',
                position: 'end',
                backgroundColor: 'rgba(100, 116, 139, 0.8)',
                font: { size: 11 }
              }
            }
          }
        }
      },
      scales: {
        y: {
          beginAtZero: true,
          max: 2.2,
          title: {
            display: true,
            text: 'Relative Risk of VTE',
            font: { size: 13, weight: '600' },
            color: '#475569'
          },
          grid: {
            color: 'rgba(148, 163, 184, 0.2)'
          },
          ticks: {
            color: '#64748b',
            stepSize: 0.5
          }
        },
        x: {
          grid: { display: false },
          ticks: {
            color: '#475569',
            font: { size: 14, weight: '600' }
          }
        }
      }
    }
  });
})();
</script>
